TradeLink Capital’s Teva Pharmaceuticals TEVA Stock Holding History

TradeLink Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-19,399	Closed	-$1.27M	–	197
2015 Q4	$1.27M	Buy	+19,399	New	+$1.2M	2.64%	4

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

TradeLink Capital's TEVA Position: Q1 2016 in Review

TradeLink Capital sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 19,399 shares — an estimated $1.27M sold.

TradeLink Capital first reported a position in TEVA in Q4 2015 and held it in 1 quarter. The position peaked at $1.27M in Q4 2015. 837 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

TradeLink Capital reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
TradeLink Capital sold 19,399 Teva Pharmaceuticals shares in Q1 2016, an estimated $1.27M.
TradeLink Capital first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 1 quarter.
TradeLink Capital's Teva Pharmaceuticals position peaked at $1.27M in Q4 2015.
837 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on TradeLink Capital's 13F filing for Q1 2016, filed 2 May 2016.